CD19 and B-cell acute lymphoblastic leukemia: Anti-CD19 CAR-T cells modified with TCRα constant chain knockout by TALENs have been shown in clinical trials to be effective and safe for patients with relapsed or refractory B cell acute lymphoblastic leukemia [174, 175].